If you have been reading about dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-28. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
=== Aftermath === In April 1864, the East Tennessee Union Convention reconvened in Knoxville, and while its delegates were badly divided, several, including Brownlow and Maynard, supported a resolution recognizing the Emancipation Proclamation. Confederate businessman Joseph Mabry and future business leaders such as Charles McClung McGhee and Peter Kern began working with Union leaders to rebuild the city. Brownlow remained vengeful, however, seizing the property of Confederate leaders J.G.M. Ramsey, William Sneed (including the Lamar House Hotel), and William Swan, and expelling known Confederate sympathizers from the city. Acts of Civil War-related violence occurred in Knoxville for years after the war. On September 4, 1865, Confederate soldier Abner Baker was lynched in Knoxville after killing a Union soldier who had killed his father. On July 10, 1868, Union major E.C. Camp shot and killed Confederate colonel Henry Ashby on Main Street in front of the courthouse over a Civil War grievance. On June 13, 1870, Joseph Mabry shot pro-Union attorney John Baxter in front of the Lamar House, capping a feud that had been building since the war. The following year, David Nelson, the son of pro-Union congressman T.A.R. Nelson, shot and killed Confederate general James Holt Clanton on Gay Street in front of the Lamar House.
== Operations == EFLM has an Executive Board and a range of committees for: science, education and training, quality and regulations, communication and professional representation. Each committee has working groups with a Chair and three full members, there is also a Young Scientist member and they may also have corresponding members, but only one member form each country is permitted. The Science Committee develops collaborative science in Laboratory Medicine between member organisations or individuals and guidelines to set standards of practice to assist member societies in providing quality patient care. The output of the scientific working groups is scientific papers and presentations which contribute to the science of laboratory medicine internationally; a list of publications can be found on the EFLM web-site (link below). Typically publications are peer-reviewed and published in the journal Clinical Chemistry and Laboratory Medicine. The Working Groups are overseen by the Chair of the Science Committee and their activities reviewed annually; scientific and clinically relevant output determine whether they continue. The Education and Training Committee runs educational activities particularly for trainees and those required to develop new skills as well as running scientific and clinical conferences, webinars, etc. The major Congress is Euromedlab held in conjunction with the IFCC, meetings are selected from bids by member societies at the annual General Meeting.
However, since opioid antagonists also block the beneficial effects of opioid analgesics, they are generally useful only for treating overdose, with use of opioid antagonists alongside opioid analgesics to reduce side effects, requiring careful dose titration and often being poorly effective at doses low enough to allow analgesia to be maintained. Naltrexone does not appear to increase risk of serious adverse events, which confirms the safety of oral naltrexone. Mortality or serious adverse events due to rebound toxicity in patients with naloxone were rare.
Premarin, the major brand of CEEs in use, is manufactured by Pfizer and was first marketed in 1941 in Canada and in 1942 in the United States. It is the most commonly used form of estrogen in menopausal hormone therapy in the United States. However, it has begun to fall out of favor relative to bioidentical estradiol, which is the most widely used form of estrogen in Europe for menopausal hormone therapy. CEEs are available widely throughout the world. An estrogen preparation very similar to CEEs but differing in source and composition is esterified estrogens. In 2020, it was the 283rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Sources: en.wikipedia.org
== Departments == Division of Basic Medical Sciences I Department of Biochemistry Department of General Biology Department of Medical Physics Division of Basic Medical Sciences II Department of Anatomy Department of General Pharmacology Department of Physiology Division of Clinical Laboratories Department of Microbiology Department of Nuclear Medicine Department of Pathology Department of Public Health Department of Radiology Division of Internal Medicine Ι Department of Internal Medicine Division of Paediatrics & Obstetrics – Gynaecology Department of Obstetrics - Gynecology Department of Paediatric Surgery Department of Paediatrics Division of Surgery Department of Anaesthesiology and Intensive Care Department of Cardiothoracic Surgery Department of Neurosurgery Department of Ophthalmology Department of Orthopaedics Department of Otorhinolaryngology Department of Surgery Department of Urology Department of Vascular Surgery
=== Molecular paint or carpet peptides === This class of peptides undergoes self-assembling on a surface and form monolayers just few nanometers thick. These types of molecular "paint" or "carpet" peptides are able to form cell patterns, interacting with or trapping other molecules onto the surface. This class of peptides consists of three segments: the head is a ligand part, which has functional groups attached for recognition by other molecules or cell surface receptors; the middle segment is a "linker", allows the head to interact at a distance away from the surface and which also controls the flexibility and the rigidity of the peptide structure; and, at the other end of the linker, a surface anchor where a chemical group on the peptide forms a covalent bond with a particular surface. This class of peptides has the unique property of being able to change molecular structure dramatically. This property is best illustrated using an example. The DAR16-IV peptide, has 16 amino acids and forms a 5 nm β-sheet structure at ambient temperatures; a swift change in structure occurs at high temperature or a change in pH when a 2.5 nm α-helix forms.
=== Benzodiazepines === Benzodiazepines are used for acute anxiety and could be added along with current use of SSRIs to stabilize a treatment. Long-term use in treatment plans is not recommended. Different kinds of benzodiazepine will vary in its pharmacological profile, including its strength of effect and time taken for metabolism. The choice of the benzodiazepine will depend on the corresponding profiles. Benzodiazepines are used for emergent or short-term management. They are not recommended as the first-line anti-anxiety drugs, but they can be used in combination with SSRIs/SNRIs during the initial treatment stage. Indications include panic disorder, sleep disorders, seizures, acute behavioral disturbance, muscle spasm and premedication and sedation for procedures.
The agency projected total energy investment of $3.4 trillion in 2026, with oil investment falling for a third consecutive year to below $500 billion, while natural gas investment rose to $330 billion—its highest in a decade—driven by new LNG projects in the United States and Qatar. Coal investment was projected to reach $180 billion, the highest since 2012. IEA Executive Director Fatih Birol described the situation as "the largest energy security crisis the world has ever faced", drawing a parallel with the oil shocks of the 1970s. Countries such as Australia and India have more sufficient reserves but face challenges with panic buying. Economies most reliant on the strait for energy imports are in Asia, with Europe also viewing the strait as vital for its energy security. The initial disruption of petroleum is expected to affect Asia the most, but Europe is likely to be hit hard in the medium-to-long term, and the UK is expected to be the worst-hit major economy. The British think tank The Food Policy Institute has warned of long-term increases in food prices due to disruption in fuel and fertiliser markets. The Strait of Hormuz is central to the global fertiliser trade. Over 30 per cent of global urea, which is widely used and produced from natural gas – is exported from Gulf countries through the Strait. Much of the cost of producing some foods, including corn and wheat, is in the cost of fertiliser, and this cost, along with rising energy costs, makes basic food production very expensive.
Since 1990, the American Dialect Society (ADS) has designated one or more words or terms to be the "Word of the Year" in the United States. In addition to the "Word of the Year", the society also selects words in other categories such as "Most Outrageous," "Most Creative," and "Most Likely to Succeed."
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.